← Back to Search

Monoclonal Antibodies

Brentuximab Vedotin + Lenalidomide + Rituximab for Diffuse Large B-Cell Lymphoma (ECHELON-3 Trial)

Phase 3
Waitlist Available
Research Sponsored by Seagen Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have you been diagnosed with diffuse large B-cell lymphoma (DLBCL)?
Have you not experienced a heart attack, stroke or blood clot in the past 6 months?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 2 years
Awards & highlights
Pivotal Trial

Summary

This trial is studying whether adding brentuximab vedotin to standard treatment with rituximab and lenalidomide may work better in treating participants with DLBCL that has come back or has not gotten better with other treatment.

Eligible Conditions
  • Lymphoma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have been diagnosed with diffuse large B-cell lymphoma (DLBCL).
Select...
You have not had a heart attack, stroke, or blood clot in the last 6 months.
Select...
Your DLBCL did not get better with treatment or came back after treatment.
Select...
You have not been diagnosed with any other type of cancer in the last 2 years.
Select...
You don't have damage to the nerves in your arms or legs.
Select...
You have been treated for DLBCL with at least two different types of medication.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall survival (OS)
Secondary study objectives
Complete response (CR) rate
Duration of response (DOR)
Incidence of adverse events
+3 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Experimental ArmExperimental Treatment3 Interventions
Brentuximab vedotin + lenalidomide + rituximab
Group II: Control ArmActive Control3 Interventions
Placebo + lenalidomide + rituximab
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Brentuximab vedotin
2012
Completed Phase 4
~210
Rituximab
1999
Completed Phase 4
~2990
Lenalidomide
2005
Completed Phase 3
~2240

Find a Location

Who is running the clinical trial?

Seagen Inc.Lead Sponsor
210 Previous Clinical Trials
74,113 Total Patients Enrolled
68 Trials studying Lymphoma
7,310 Patients Enrolled for Lymphoma
Medical MonitorStudy DirectorSeagen Inc.
1,678 Previous Clinical Trials
989,873 Total Patients Enrolled
52 Trials studying Lymphoma
12,999 Patients Enrolled for Lymphoma
Evelyn Rustia, MDStudy DirectorSeagen Inc.
1 Previous Clinical Trials
466 Total Patients Enrolled
Brandon Croft, PharmDStudy DirectorSeagen Inc.
3 Previous Clinical Trials
681 Total Patients Enrolled
Robert Sims, MDStudy DirectorSeagen Inc.
2 Previous Clinical Trials
213 Total Patients Enrolled
2 Trials studying Lymphoma
213 Patients Enrolled for Lymphoma

Media Library

Brentuximab Vedotin (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04404283 — Phase 3
Lymphoma Research Study Groups: Control Arm, Experimental Arm
Lymphoma Clinical Trial 2023: Brentuximab Vedotin Highlights & Side Effects. Trial Name: NCT04404283 — Phase 3
Brentuximab Vedotin (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04404283 — Phase 3
Lymphoma Patient Testimony for trial: Trial Name: NCT04404283 — Phase 3
~42 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top